目的 對重組人干擾素α-2b聯(lián)合保婦康栓治療人乳頭瘤病毒（HPV）感染進行成本-效果分析，為臨床合理用藥和醫(yī)療衛(wèi)生決策提供循證依據(jù)。方法 從醫(yī)療保健系統(tǒng)角度建立決策樹模型，對重組人干擾素α-2b單用（對照組）或聯(lián)合保婦康栓（每次1粒或每次2粒，分別為聯(lián)合用藥組1和聯(lián)合用藥組2）治療HPV感染進行成本-效果分析。效果指標(biāo)采用Meta分析獲得HPV轉(zhuǎn)陰率，成本數(shù)據(jù)根據(jù)官方網(wǎng)站發(fā)布的藥品價格和診療價格獲得。采用單因素敏感性分析對成本-效果分析的結(jié)果進行驗證。結(jié)果 對照組、聯(lián)合用藥組1和聯(lián)合用藥組2的HPV轉(zhuǎn)陰率分別為66.40%、87.00%、85.11%，對應(yīng)的治療總成本分別為1 217.20、1 303.80、1 435.38元。聯(lián)合用藥組1與對照組相比，增量成本效果比（ICER）為393.62元，低于1倍2021年中國人均GDP（80 976.00元），聯(lián)合用藥組1，即重組人干擾素α-2b聯(lián)合保婦康栓（每次1粒）更具有成本-效果優(yōu)勢。單因素敏感性分析顯示，聯(lián)合用藥組HPV轉(zhuǎn)陰率是對ICER影響最大的因素。結(jié)論 重組人干擾素α-2b聯(lián)合保婦康栓（每次1粒）治療HPV感染更具經(jīng)濟性。

Objective To conduct the cost-effectiveness analysis of recombinant human interferon α-2b combined with Baofukang Suppository in treatment of Human papilloma-virus (HPV), and to provide evidence-based reference for rational drug use and medical and healthy decision-making. Methods From the perspective of the healthcare system, a decision tree model was established to analyze the cost-effectiveness of recombinant human interferon α-2b singly or combined with Baofukang Suppository (1 or 2 capsules per time for combination group 1 and combination group 2, respectively). The effectiveness was obtained through Meta-analysis, and the cost was obtained according to the drug price and diagnosis and treatment price published on the official websites. Single-factor sensitivity analysis was performed to validate the results of cost-effectiveness analysis. Results The HPV negative rates of the recombinant human interferon α-2b single group (control group), the first combination group (one capsule once time), and the second combination group (two capsule once time) were 66.40%, 87.00%, and 85.11% respectively. And the corresponding total cost of treatment was separately 1 217.20 yuan, 1 303.80 yuan, and 1 435.38 yuan. Compared with the single group, the incremental cost-effect ratio (ICER) of combination group 1 was 393.62 yuan, which was less than one time the average GDP of the Chinese in 2021 (80 976.00 yuan). Therefore, the combination group 1, that is, recombinant human interferon α-2b combined with one capsule/time of Baofukang Suppository, has a cost-effect advantage. Single factor sensitivity analysis showed that the treatment effectiveness of these groups was the most important factor affecting the ICER. Conclusion The recombinant human interferon α-2b combined with one capsule/time of Baofukang Suppository is economical in the HPV treatment.

R984